These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
136 related items for PubMed ID: 2868560
1. Effect of perfluorochemical (Fluosol-DA) on infarct morphology in dogs. Kolodgie FD, Dawson AK, Forman MB, Virmani R. Virchows Arch B Cell Pathol Incl Mol Pathol; 1985; 50(2):119-34. PubMed ID: 2868560 [Abstract] [Full Text] [Related]
2. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia. Kolodgie FD, Dawson AK, Roden DM, Forman MB, Virmani R. Am Heart J; 1986 Dec; 112(6):1192-201. PubMed ID: 3788766 [Abstract] [Full Text] [Related]
3. The effect of perfluorochemical fluosol-DA (20%) on myocardial infarct healing in the rabbit. Virmani R, Osmialowski AF, Kolodgie FD, Forman MB. Am J Cardiovasc Pathol; 1990 Dec; 3(1):69-80. PubMed ID: 2331363 [Abstract] [Full Text] [Related]
4. Beneficial long-term effect of intracoronary perfluorochemical on infarct size and ventricular function in a canine reperfusion model. Forman MB, Puett DW, Wilson BH, Vaughn WK, Friesinger GC, Virmani R. J Am Coll Cardiol; 1987 May; 9(5):1082-90. PubMed ID: 3571747 [Abstract] [Full Text] [Related]
5. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation. Bajaj AK, Cobb MA, Virmani R, Gay JC, Light RT, Forman MB. Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160 [Abstract] [Full Text] [Related]
6. Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model. Absence of a role of polymorphonuclear leukocytes. Kolodgie FD, Farb A, Carlson GC, Wilson PS, Virmani R. J Am Coll Cardiol; 1994 Oct; 24(4):1098-108. PubMed ID: 7930204 [Abstract] [Full Text] [Related]
7. Pharmacologic perturbation of neutrophils by Fluosol results in a sustained reduction in infarct size in the canine model of reperfusion. Forman MB, Pitarys CJ, Vildibill HD, Lambert TL, Ingram DA, Virmani R, Murray JJ. J Am Coll Cardiol; 1992 Jan; 19(1):205-16. PubMed ID: 1729335 [Abstract] [Full Text] [Related]
8. Effect of fluocarbon exchange transfusion on myocardial infarction size in dogs. Nunn GR, Dance G, Peters J, Cohn LH. Am J Cardiol; 1983 Jul; 52(1):203-5. PubMed ID: 6858913 [Abstract] [Full Text] [Related]
9. Reduction of infarct size with intracoronary perfluorochemical in a canine preparation of reperfusion. Forman MB, Bingham S, Kopelman HA, Wehr C, Sandler MP, Kolodgie F, Vaughn WK, Friesinger GC, Virmani R. Circulation; 1985 May; 71(5):1060-8. PubMed ID: 3986976 [Abstract] [Full Text] [Related]
10. Limitation of no reflow injury by blood-free reperfusion with oxygenated perfluorochemical (Fluosol-DA 20%). Kolodgie FD, Virmani R, Farb A. J Am Coll Cardiol; 1991 Jul; 18(1):215-23. PubMed ID: 2050924 [Abstract] [Full Text] [Related]
11. Failure of fluosol DA to enhance the ultrasonic image of infarcted myocardium. Vasey CG, Armstrong WF, West SR, Waller BF, Dillon JC, Feigenbaum H. J Clin Ultrasound; 1986 Oct; 14(8):613-8. PubMed ID: 3095392 [Abstract] [Full Text] [Related]
12. Dose-dependent reduction of myocardial infarct size with the perfluorochemical Fluosol-DA. Rice HE, Virmani R, Hart CL, Kolodgie FD, Farb A. Am Heart J; 1990 Nov; 120(5):1039-46. PubMed ID: 2239656 [Abstract] [Full Text] [Related]
13. Effects of intracoronary infusion of arterial blood or Fluosol-DA 20% on regional myocardial metabolism and function during brief coronary artery occlusions. Tokioka H, Miyazaki A, Fung P, Rajagopalan RE, Kar S, Meerbaum S, Corday E, Drury JK. Circulation; 1987 Feb; 75(2):473-81. PubMed ID: 2948736 [Abstract] [Full Text] [Related]
14. Cardioplegic protection with hypothermic K-Fluosol DA and K/Mg-Fluosol DA solutions. Kyösola K, Harjula A, Mattila S, Aalto-Setälä K, Mattila I, Mattila P, Salmenperä M, Merikallio E. Scand J Thorac Cardiovasc Surg; 1985 Feb; 19(3):267-72. PubMed ID: 4081676 [Abstract] [Full Text] [Related]
15. Myocardial protection by perfluorochemical infusion during transient ischemia produced by balloon coronary occlusion. Virmani R, Kolodgie FD, Osmialowski A, Zimmerman P, Mergner W, Forman MB. Am Heart J; 1988 Aug; 116(2 Pt 1):421-31. PubMed ID: 2969667 [Abstract] [Full Text] [Related]
16. Protective effect of Fluosol-DA in acute cerebral ischemia. Peerless SJ, Ishikawa R, Hunter IG, Peerless MJ. Stroke; 1981 Aug; 12(5):558-63. PubMed ID: 6795765 [Abstract] [Full Text] [Related]
17. Preservation of endothelial cell structure and function by intracoronary perfluorochemical in a canine preparation of reperfusion. Forman MB, Puett DW, Bingham SE, Virmani R, Tantengco MV, Light RT, Bajaj A, Price R, Friesinger G. Circulation; 1987 Aug; 76(2):469-79. PubMed ID: 3608128 [Abstract] [Full Text] [Related]
18. Comparison of the effect of fluosol DA and dextran 40 on regional cerebral blood flow, infarction size, and mortality in cats with temporary occlusion of the middle cerebral artery. Kolluri S, Heros RC, Hedley-Whyte ET, Vonsattel JP, Miller D, Zervas NT. Surg Neurol; 1986 Jul; 26(1):3-8. PubMed ID: 2424107 [Abstract] [Full Text] [Related]
19. Experimental studies on fluosol DA administration in acute pancreatitis. Ohyanagi H, Ohashi O, Nakayama S, Yamamoto M, Okumura S, Saitoh Y. Biomater Artif Cells Artif Organs; 1988 Jul; 16(1-3):585-94. PubMed ID: 3179491 [Abstract] [Full Text] [Related]
20. Modification of cerebral ischemia with Fluosol. Peerless SJ, Nakamura R, Rodriguez-Salazar A, Hunter IG. Stroke; 1985 Jul; 16(1):38-43. PubMed ID: 3966263 [Abstract] [Full Text] [Related] Page: [Next] [New Search]